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summARy – ovarian hyperstimulation syndrome is the most serious iatrogenic complication 
resulting from ovarian stimulation. Currently there is no clear evidence of absolute efficacy for most 
of standard preventive and curative methods. Recent studies indicate that human chorionic gona-
dotropin increases vascular endothelial growth factor, vascular endothelial cadherin and vascular 
permeability via endothelial adherence junctions. vascular endothelial growth factor plays a pivotal 
role in the pathophysiology of the condition and therefore vascular endothelial factor antagonism 
has been suggested for the prevention of the syndrome. since vascular endothelial growth factor 
is also a physiological regulator of folliculogenesis, progesterone secretion and endometrial angio-
genesis, its complete inactivation by specific blockers could produce undesirable effects interfering 
with early pregnancy development and therefore they cannot be used clinically. Recently, low do-
ses of dopamine agonists (cabergoline) have been shown to counteract vascular endothelial growth 
factor induced vascular hyperpermeability, reducing the incidence of the syndrome by prophylactic 
treatment without compromising pregnancy outcome. The absence of undesirable side effects could 
make cabergoline an effective and safe etiologic approach for the prevention and treatment of the 
syndrome. A novel approach has suggested that metformin may also be helpful in the syndrome 
prevention in women with or without polycystic ovary disease. 
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Introduction
The ovarian hyperstimulation syndrome (ohss) 
is a rare iatrogenic complication of ovarian stimula-
tion, occurring during the luteal phase or early preg-
nancy. it is typically associated with the use of exog-
enous gonadotropins or occasionally with clomiphene 
citrate, and extremely rarely in a spontaneous cycle 
during early pregnancy1. As the overall incidence of 
clinically relevant ohss is up to 10% of cycles and 
severe forms of ohss arise in 0.5%-5% of in vitro 
fertilization (ivf), it is important for all clinicians to 
be aware of the strategies for its prevention. since this 
is a potentially life-threatening syndrome, it is unfor-
tunate that despite increased awareness of the well-
known prognostic variables ohss may not always be 
prevented2. 
vascular endothelial growth factor (vegf), also 
known as vascular permeability factor, has emerged 
as one of the factors most likely to be involved in 
the pathophysiology of ohss. Recent studies indi-
cate that human chorionic gonadotropin (hCg) is 
the main factor that triggers ohss and seems to be 
the pivotal stimulus of the syndrome because elimi-
nation of hCg will prevent the full-blown picture 
of the syndrome3. it has been clearly demonstrated 
that hCg increases vegf and its vegf-2 recep-
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tors in human granulosa-lutein cells and raises se-
rum vegf concentrations. vegf acts through the 
vegf receptor 2 (vegfR-2) on the endothelial 
cells and it is the main mediator responsible for the 
prominent role in the pathologic increase of vascular 
permeability. similarly, hCg and vegf individu-
ally produce a significant increase in ve-cadherin 
release, which is involved in the loosening of en-
dothelial intercellular junctions. ve-cadherin is a 
soluble cell adhesion molecule that may play a key 
role in the pathophysiology and progression of vas-
cular hyperpermeability4,5.
The hallmark of ohss is an increase in capillary 
permeability of the ovaries and mesothelial surfaces, 
resulting in extravasation of protein-rich fluid into 
the third space, which in turn causes hypovolemia, 
reduced organ perfusion and the risk of thromboem-
bolism. A critical condition develops with massive 
ascites or pleural effusion, dyspnea, hemoconcentra-
tion and oliguria. The manifestations of ohss are 
believed to be the result of increased capillary perme-
ability and range from mild abdominal discomfort to 
severe, life-threatening illness6.
in the past, several preventive and curative ap-
proaches were suggested. As to date, the condition of 
ohss is not yet completely understood. no known 
pharmacological intervention that fully prevents the 
development of the syndrome and no completely cu-
rative therapy has yet been detected. however, ow-
ing to recent insights into the pathophysiology of the 
syndrome, new proposals and strategies of prevention 
have been reported4,5. ohss continues to be among 
the most serious complications of ovulation induction 
with exogenous gonadotropins. physicians who pre-
scribe medications with the potential to cause ohss 
require knowledge of the pathophysiological mecha-
nisms of the disease and experience with ovulation 




The oldest and the most effective method in pre-
venting ohss has been abandonment of the cycle, 
however, only 11% of physicians would consider can-
celling because of high costs and tremendous effort 
invested by the couple. withholding hCg and cycle 
cancellation was the most commonly used method of 
preventing ohss, but at the expense of losing cycle 
with heavy psychological and financial burdens upon 
the patient7.
Coasting 
Coasting with cessation of gonadotropins until se-
rum estradiol (e2) levels drop to a safe level has been 
widely adopted to reduce ohss, however, prolonged 
coasting has the drawback of a reduced pregnancy rate. 
it is a good alternative that can be used to avoid cycle 
cancellation in extremely high responders to ovulation 
induction, who have a high risk of developing severe 
ohss. even if ohss develops after coasting, both 
its incidence and severity will be diminished. until 
multifactorial etiopathogenesis of ohss is completely 
understood, absolute prevention will not be possible, 
but coasting is definitely of great benefit8.
Stimulation protocols 
The risk of ohss is particularly evident when 
ovulation induction for ivf procedure is performed 
with elevated gonadotropin dosages. it is advisable 
to use a low starting dose of 150 iu for all patients 
at a possible risk of ohss, irrespective of their age. 
The low-dose, step-up protocol and the step-down 
protocol are associated with a low risk of ohss9. 
The use of gonadotropin releasing hormone (gnRh) 
agonists, especially of a long protocol, increases the 
incidence of ohss. however, the use of gnRh an-
tagonists significantly reduce ohss incidence at the 
expense of lower ongoing pregnancy rates10. hCg 
is currently used as a standard method for trigger-
ing oocyte maturation, although it is the main fac-
tor that increases ohss risk. Therefore, it has been 
suggested that a lower dose of urinary hCg (e.g., 
5,000 vs. standard 10,000 iu dosage) or 250 mcg of 
recombinant hCg be used for ovulation induction 
in the presence of risk factors of ohss11. Alterna-
tively, a gnRh agonist or recombinant luteinizing 
hormone (lh) might be used to promote final oo-
cyte maturation and induce ovulation12. Regardless 
of whether hCg or its alternatives are administered 
at midcycle, the use of progesterone for luteal phase 
support rather than supplemental doses of hCg may 
further reduce the risk of ohss13.
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Early unilateral follicular aspiration (EUFA)
in the first report, eufA was applied in patients 
at risk of ohss 12 h after hCg administration, fol-
lowed by regular oocyte retrieval 36 h later. it was sug-
gested that intra-ovarian bleeding induced by follicu-
lar aspiration of granulosa cells from one ovary would 
limit the production of ovarian mediators of ohss 
and thus reduce the risk of developing severe ohss. 
The method of post-hCg-aspiration in one ovary was 
described as a simple and effective method that pre-
vented the development of ohss14. however, these 
data are contradictory, with results of a prospective 
randomized study comparing unilateral ovarian aspi-
ration with the coasting, where neither method com-
pletely prevented the occurrence of severe ohss15.
Treatment
Albumin
A Cochrane review reported a clear benefit from 
prophylactic administration of albumin at the time of 
oocyte retrieval and it could be helpful in the preven-
tion of severe ohss in high-risk patients. Albumin 
seems to have osmotic and transport functions, draw-
ing extracellular fluid into the circulation and binding 
or inactivating the vasoactive substances responsible 
for the pathogenesis of ohss16. however, in a recent 
prospective randomized study, it was found that hu-
man albumin did not seem to either prevent or reduce 
the incidence of severe ohss. without a concomi-
tant reduction in vascular permeability, however, the 
effect of albumin on intravascular volume and hemat-
ocrit may be of short duration due to its diffusion into 
the extravascular space, exacerbating both ascites and 
pleural effusions17.
Embryo cryopreservation 
elective transfer of a single zona-free day 5 em-
bryo and freezing of the supernumerary embryos or 
cryopreservation of all embryos for postponement 
of transfer can prevent the occurrence of late ohss 
from pregnancy. however, it does not prevent early 
ohss development due to exogenous hCg admin-
istration. The management based on elective 2 pro-
nucleate embryo cryopreservation with subsequent 
thaw and grow-out to blastocyst stage for transfer did 
not appear to compromise embryo viability or overall 
reproductive outcome. for these patients, immediate 
elective embryo cryopreservation and delay of embryo 
transfer by as little as 30 days allowed for satisfactory 
conclusion of the ivf sequence, yielding a live birth-
delivery rate of 33% per initiated cycle and 43.6% per 
transfer18.
Paracentesis
The vast majority of patients with severe ohss 
had their condition successfully managed as outpa-
tients with the use of aggressive transvaginal paracen-
tesis. immediately after paracentesis, characteristic 
hemodynamic changes occurred including decreased 
intra-abdominal pressure, improved venous return, 
and improved renal perfusion19. in addition to the 
mechanical improvements in blood flow occurring 
after removal of ascites fluid, the other mechanisms 
by which paracentesis has been proposed to improve 
condition in ohss is by direct removal of the inflam-
matory, vasodilatatory, and angiogenic substances re-
leased by hyperstimulated ovaries20.
New therapeutic approaches
until recently, the pathophysiology of ohss was 
poorly understood and it is still a complex process. 
Therefore, there is no standard pharmacological in-
tervention that fully prevents the development of the 
syndrome and no completely curative therapy7. how-
ever, since recently several observations from animal 
studies suggest that development of ohss is prob-
ably mediated by increased ovarian production and 
secretion of vasoactive substances, with vegf being 
the main candidate among them. vegf signaling 
through vegfR-2 stimulates not only new blood 
vessels in follicular growth, luteal function and em-
bryo implantation, but it is also an important regula-
tor of vascular permeability3-5. 
Natural inhibitors
it is surprising that, among women who display 
high parameters of ovarian response and who should 
therefore run the same risk of ohss, only some de-
velop the syndrome. This discrepancy may be related 
to soluble proteins that bind to vegf. The vegf 
soluble receptor-1 (svegfR-1) is reported to act as 
a modulator of vegf bioactivity, which competes 
with the full-length vegfR to bind to vegf and 
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inhibit vascular permeability21. Another molecule, 
alfa2-macroglobulin, a major serum-binding protein 
associated with tissue remodeling during ovulation 
and corpus luteum maintenance, is also thought to 
determine the availability of free vegf to bind to 
vegfR-222. during the luteal phase, hyperstimu-
lated patients who developed ohss presented total 
and free vegf levels significantly higher than those 
observed in women who had not undergone hyper-
stimulation, including those with a strong ovarian 
response. high levels of these proteins may decrease 
free vegf and protect against ohss. women who 
did not develop ohss, among whom both normal 
and strong responses to stimulation were observed, 
presented significantly higher plasma levels of natural 
antagonist svegfR-1. Although the ability of alfa2-
macroglobulin to bind and inactivate vegf is well 
known, its relevance in ohss is not yet confirmed23. 
VEGFR-2 inhibitor (SU5416) 
validation of the importance of the vegf/veg-
fR-2 pathway in ohss comes from the findings in 
which development of the syndrome could be pre-
vented by the administration of su5416, a vegfR-2 
inhibitor, a substance that blocks vegfR-2 phos-
phorylation. it was demonstrated for the first time 
that hCg-induced changes in vascular permeability 
could be prevented by interference with the vegf/
vegfR-2 signaling pathway24. unfortunately, su 
5416 cannot be used clinically due to its side effects 
(thromboembolism, vomiting) and the possibility that 
it might interfere with early pregnancy development 
by blocking implantation related ovarian and uterine 
angiogenesis25.
Dopamine agonists 
There is a need to pharmacologically segregate the 
permeability component from the angiogenic por-
tion of the vegf/vegfR-2 pathway to treat this 
syndrome. it was recently found that dopamine (dp) 
or dopamine receptor 2 (dp-r2) agonists transacted 
inhibition of vegfR-2 dependent vascular perme-
ability and angiogenesis through dp-r2 of endothelial 
cells. Administration of high doses of dp-r2 agonists 
simultaneously blocks tumor related angiogenesis 
and vascular permeability in a mouse cancer model 
by interfering with vegf/vegfR-2 signaling. In 
vitro studies suggested that the molecular mecha-
nism underlying this action involved internalization 
of vegfR-2 induced by activation of dp-r2. The re-
ceptor became unreachable for vegf, and this led to 
a general inhibition of the vegf/vegfR-2 path-
way, which resulted in not only decreased vascular 
permeability but also angiogenesis26. it is well known 
that doses of dp-r2 agonists much lower than those 
used in the tumor model are sufficient to activate the 
dp-r2 pathway, as demonstrated by the fact that they 
decrease prolactin secretion by the pituitary gland. 
Thus, low-dose dp-r2 agonists are successfully used 
for the treatment of hyperprolactinemia in humans. 
interestingly, at these low doses, dp-r2 agonists do 
not exert antiangiogenic activity because physiologi-
cal states of high level vegfR-2-dependent vascular 
activity like formation of corpora lutea or pregnancy 
development are not affected27. using a prolactin-sup-
plemented ohss rat model, it was shown that a low 
dose of dp-r2 agonist cabergoline retained the ability 
to decrease vascular hyperpermeability without af-
fecting angiogenesis. Cabergoline action seems to be 
mediated through activation of dp-r2 because endog-
enous prolactin secretion, a marker of dp-r2 activity, 
was consistently reduced by the drug administration. 
Activation of dp-r2 is associated with changes in the 
vegf/vegfR-2 pathway, as indicated by partial 
blockage of vegfR-2-specific phosphorylation site. 
These findings indicate that the permeability compo-
nent of vegf/vegfR-2 pathway can be segregated 
from the angiogenic component by dp-r2 agonists 
in a dose-dependent manner. Cabergoline blocks not 
only hyperpermeability in the rat ohss model but 
also a similar condition in human, which can occur 
during infertility treatment. owing to these find-
ings, a new clinical application for cabergoline or a 
specific nontoxic treatment of ohss has been sug-
gested for the first time, without affecting reproduc-
tive angiogenesis28. in several recent studies, these 
beneficial effects were confirmed and dp-r2 agonists 
were proposed as a prophylactic treatment of ohss 
in women at high risk in ivf treatment cycles. The 
preventive dose of 0.5 mg of oral cabergoline per day 
for 1 to 3 weeks starting on the day of hCg admin-
istration has been suggested in most studies3,4,29,30. in 
a recent meta-analysis of 4 randomized trials includ-
ing 570 women, there was evidence for a statistically 
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significant reduction in the incidence of ohss in the 
cabergoline group, with an absolute risk reduction by 
12%. however, there was no statistically significant 
evidence for a reduction in severe ohss and no evi-
dence for difference in the clinical pregnancy rate. it 
was concluded that prophylactic treatment with the 
dopamine agonist cabergoline reduced the incidence, 
but not the severity of ohss, without compromising 
pregnancy outcome31. in spite of these beneficial ef-
fects of the dopamine agonist cabergoline on vascular 
permeability without compromising implantation and 
pregnancy rates, this treatment would complement 
the ongoing progress with other procedures such as in 
vitro maturation and oocyte vitrification and enable 
physicians to predict and prevent ohss32. 
Metformin
women affected by polycystic ovary disease are a 
subgroup of patients at the highest risk of ohss, with 
an incidence of 6% in these women compared with 1% 
in the general infertile population after ovulation in-
duction. A recent meta-analysis has shown the poly-
cystic ovary disease women treated with metformin 
to have a statistically significantly lower incidence of 
ohss compared with the untreated group. Although 
the mechanism of action of metformin is unclear, it 
seems that the reduction of ovarian reserve, as dem-
onstrated by the reduction of antimüllerian hormone 
values, and a reduced insulin dependent vegf pro-
duction, have been suggested33. moreover, a novel ap-
proach has been suggested in a recent pilot study, i.e. 
that metformin as a safe and inexpensive drug may 
also help in the prevention of ohss development in 
women without polycystic ovary disease34.
Conclusion 
until multifactorial etiopathogenesis of ohss is 
completely understood, absolute prevention and treat-
ment of ohss will not be possible, and are currently 
based on an empirical and symptomatic approach. 
due to the clear lack of efficacy for most of the stan-
dard preventive and curative measures in the past, 
there was an urgent need for further investigations 
in the pathophysiology of this syndrome. Recent ob-
servations from several studies suggest that vegf or 
vascular permeability factor plays a pivotal role in in-
creasing vascular permeability in hyperstimulated pa-
tients under the influence of hCg. Therefore, it seems 
that the most promising way to prevent ohss might 
be hCg dose tapering or use of its alternatives to re-
duce vegf production. in addition to cabergoline-
mediated vegf antagonism by dp-2r stimulation 
in combination with metformin promote an effective 
step further in the etiologic therapeutic approach to 
ohss. 
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sažetak
liJečenJe ovARiJsKog hipeRsTimulACiJsKog sindRomA: novi uvidi
M. Kasum i S.Orešković
ovarijski hiperstimulacijski sindrom je najozbijnija jatrogena komplikacija koja nastaje nakon stimulacije jajnika. Za-
sad nema jasnih dokaza o apsolutnoj djelotvornosti većine standardnih i preventivnih i kurativnih metoda. novije studije 
pokazuju da humani korionski gonadotropin povisuje vaskularni čimbenik rasta, vaskularni endotelni kaderin i vaskularnu 
propusnost na spojevima adherentnog endotela. Kako vaskularni endotelni čimbenik rasta igra ključnu ulogu u patofiziolo-
giji sindroma, ukazuje se na onemogućavanje djelovanja vaskularnog čimbenika rasta u prevenciji bolesti. budući da je va-
skularni čimbenik rasta ujedno i fiziološki regulator folikulogeneze, stvaranja progesterona i krvnih žila endometrija, nje-
gova bi potpuna inaktivacija specifičnim blokatorima dovela do neželjenih nuspojava koje bi ometale razvoj rane trudnoće, 
što onemogućuje njihovu kliničku primjenu. odnedavno se pokazalo kako niske doze agonista dopamina (kabergolin) 
suzbijaju pojačanu vaskularnu propusnost izazvanu vaskularnim endotelnim čimbenikom rasta, smanjujući profilaktično 
pojavnost sindroma bez nepovoljnog djelovanja na ishod trudnoće. Zbog izostanka nepoželjnih nuspojava kabergolin bi 
mogao biti djelotvoran i siguran u etiološkom pristupu te u prevenciji i liječenju sindroma. noviji pristup ukazuje na to da 
primjena metformina može isto koristiti u prevenciji sindroma kod žena s policističnim jajnicima ili bez njih.
Ključne riječi: Sindrom hiperstimulacije jajnika – terapija; Indukcija ovulacije – štetni učinci; Indukcija ovulacije – čimbenici 
rizika; Agonisti dopamina

